Novo Nordisk A/S
NVONYSEHealthcare● Active
$41.27
$-1.69(-3.93%)
Market Cap$183.4B
P/E Ratio—
52W High$81.44
52W Low$35.12
Novo Nordisk A/S (NVO) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
NVO · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 6, 2026EPS Actual
$1.04
Est. $0.87 · +19.5%
Revenue
$11.02B
Est. $10.86B · +1.5%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 6, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue🔥 7-Quarter EPS Beat Streak
NVO reports quarterly as a NYSE-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$1.19
Rev. $0.35B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$1.19
Rev. Est.$0.35B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 5, 2026 | $0.83 | — | — | — | $11.21B | — |
| ▲ Q2 FY2026 | May 6, 2026 | $0.87 | $1.04 | +19.5% | $11.02B | $10.86B | +1.5% |
| ▲ Q1 FY2026 | Feb 3, 2026 | $0.90 | $1.00 | +11.1% | $12.50B | $12.13B | +3.1% |
| ▲ Q4 FY2025 | Nov 5, 2025 | $0.77 | $1.02 | +32.5% | $11.78B | $12.37B | -4.8% |
| ▲ Q3 FY2025 | Aug 6, 2025 | $0.93 | $0.97 | +4.3% | $12.13B | $12.30B | -1.4% |
| — Q2 FY2025 | May 7, 2025 | $0.92 | $0.92 | +0.0% | $11.49B | $11.94B | -3.8% |
| ▲ Q1 FY2025 | Feb 5, 2025 | $0.88 | $0.91 | +3.4% | $11.86B | $11.55B | +2.7% |
| ▲ Q4 FY2024 | Nov 6, 2024 | $0.87 | $0.88 | +1.4% | $10.68B | $10.48B | +1.9% |
Q3 FY2026
Aug 5, 2026
EPS Actual
—
EPS Est.
$0.83
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 6, 2026Beat
EPS Actual
$1.04
EPS Est.
$0.87
EPS Surpr.
+19.5%
Revenue
$11.02B
Q1 FY2026
Feb 3, 2026Beat
EPS Actual
$1.00
EPS Est.
$0.90
EPS Surpr.
+11.1%
Revenue
$12.50B
Q4 FY2025
Nov 5, 2025Beat
EPS Actual
$1.02
EPS Est.
$0.77
EPS Surpr.
+32.5%
Revenue
$11.78B
Q3 FY2025
Aug 6, 2025Beat
EPS Actual
$0.97
EPS Est.
$0.93
EPS Surpr.
+4.3%
Revenue
$12.13B
Q2 FY2025
May 7, 2025
EPS Actual
$0.92
EPS Est.
$0.92
EPS Surpr.
+0.0%
Revenue
$11.49B
Q1 FY2025
Feb 5, 2025Beat
EPS Actual
$0.91
EPS Est.
$0.88
EPS Surpr.
+3.4%
Revenue
$11.86B
Q4 FY2024
Nov 6, 2024Beat
EPS Actual
$0.88
EPS Est.
$0.87
EPS Surpr.
+1.4%
Revenue
$10.68B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $5.02 | $5.24 | $5.58 | 1 |
| Q3 FY2027 | $5.42 | $5.65 | $6.03 | 1 |
| Q2 FY2027 | $5.62 | $5.86 | $6.25 | 1 |
| Q1 FY2027 | $5.85 | $6.10 | $6.51 | 1 |
| Q4 FY2026 | $4.58 | $4.77 | $5.09 | 1 |
| Q3 FY2026 | $4.82 | $5.08 | $5.47 | 3 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $80.8B | $83.4B | $87.6B | 3 |
| Q3 FY2027 | $76.4B | $78.9B | $82.9B | 3 |
| Q2 FY2027 | $77.1B | $79.6B | $83.7B | 3 |
| Q1 FY2027 | $75.6B | $78.0B | $82.0B | 3 |
| Q4 FY2026 | $73.3B | $75.7B | $79.6B | 5 |
| Q3 FY2026 | $71.0B | $72.5B | $73.4B | 6 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 6, 2026 | +19.5% | $44.87 | $45.76 | +1.98% |
| ▲ Q1 FY2026 | Feb 3, 2026 | +11.1% | $58.93 | $50.30 | -14.64% |
| ▲ Q4 FY2025 | Nov 5, 2025 | +32.5% | $48.25 | $48.46 | +0.44% |
| ▲ Q3 FY2025 | Aug 6, 2025 | +4.3% | $47.22 | $45.38 | -3.90% |
| ▲ Q2 FY2025 | May 7, 2025 | +0.0% | $66.29 | $67.55 | +1.90% |
| ▲ Q1 FY2025 | Feb 5, 2025 | +3.4% | $82.62 | $85.73 | +3.76% |
| ▲ Q4 FY2024 | Nov 6, 2024 | +1.4% | $110.13 | $105.36 | -4.33% |
| ▼ Q3 FY2024 | Aug 7, 2024 | -5.9% | $130.12 | $119.23 | -8.37% |
Q2 FY2026+1.98%
Report Date
May 6, 2026
EPS Beat/Miss
+19.5%
Price Before
$44.87
Price After
$45.76
Q1 FY2026-14.64%
Report Date
Feb 3, 2026
EPS Beat/Miss
+11.1%
Price Before
$58.93
Price After
$50.30
Q4 FY2025+0.44%
Report Date
Nov 5, 2025
EPS Beat/Miss
+32.5%
Price Before
$48.25
Price After
$48.46
Q3 FY2025-3.90%
Report Date
Aug 6, 2025
EPS Beat/Miss
+4.3%
Price Before
$47.22
Price After
$45.38
Q2 FY2025+1.90%
Report Date
May 7, 2025
EPS Beat/Miss
+0.0%
Price Before
$66.29
Price After
$67.55
Q1 FY2025+3.76%
Report Date
Feb 5, 2025
EPS Beat/Miss
+3.4%
Price Before
$82.62
Price After
$85.73
Q4 FY2024-4.33%
Report Date
Nov 6, 2024
EPS Beat/Miss
+1.4%
Price Before
$110.13
Price After
$105.36
Q3 FY2024-8.37%
Report Date
Aug 7, 2024
EPS Beat/Miss
-5.9%
Price Before
$130.12
Price After
$119.23
Avg Beat Reaction-2.11%
Avg Miss Reaction-8.37%
Beat Rate7 / 8 quarters
Largest Move-14.64% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: NVO ends December
Novo Nordisk A/S (NVO) most recently reported earnings on May 6, 2026 for Q2 FY2026, posting EPS of $1.04 — beating the analyst consensus of $0.87 by +19.5%. NVO has beaten EPS estimates for 7 consecutive quarters. The next NVO earnings date is expected around September 1, 2026.
Each quarter, investors track NVO earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. NVO revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
NVO's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
NVO earnings · 5 questionsNovo Nordisk A/S's next earnings report is expected around September 1, 2026. NVO typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; NVO historically reports after market close (AMC).
NVO earnings datewhen is NVO earningsNVO next earnings datewhen does NVO report earningsNVO earnings calendar
▸ Source: FMP · Novo Nordisk A/S SEC filings · US GAAP · Novo Nordisk A/S SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026